Home > Riviste > Minerva Respiratory Medicine > Fascicoli precedenti > Minerva Respiratory Medicine 2022 September;61(3) > Minerva Respiratory Medicine 2022 September;61(3):138-45

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Respiratory Medicine 2022 September;61(3):138-45

DOI: 10.23736/S2784-8477.22.01999-4

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

Paraoxonase-1 in stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

Elisabetta ZINELLU 1, Angelo ZINELLU 2, Maria C. PAU 3, Alessandro G. FOIS 1, 3, Sabrina MELLINO 2, Arduino A. MANGONI 4, Ciriaco CARRU 2, Pietro PIRINA 1, 3

1 Unit of Clinical and Interventional Pulmonology, University Hospital Sassari, Sassari, Italy; 2 Department of Biomedical Sciences, University of Sassari, Sassari, Italy; 3 Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 4 College of Medicine and Public Health, Department of Clinical Pharmacology, Flinders Medical Center, Flinders University, Bedford Park, Australia



INTRODUCTION: Oxidative stress plays a critical pathophysiological role in chronic obstructive pulmonary disease (COPD). An impairment in antioxidant defense systems, which include the enzyme paraoxonase1 (PON-1), have been reported in COPD patients. This systematic review and meta-analysis investigated the association between serum PON1 and COPD.
EVIDENCE ACQUISITION: A systematic search was performed using the following terms and their combination: “paraoxonase-1” or “PON-1” and “chronic obstructive pulmonary disease” or “COPD” in PubMed, Web of Science, Scopus, and Google Scholar, from inception to October 2021. Standardized mean differences (SMDs) of serum PON-1 concentrations between stable COPD patients and non-COPD subjects were calculated.
EVIDENCE SYNTHESIS: Thirteen studies were included in the meta-analysis. Pooled results showed that serum PON-1 concentrations were significantly lower in patients with COPD (SMD=-1.12, 95% CI: -1.72 to -0.53; P<0.001).
CONCLUSIONS: The observed reduction of PON-1 concentrations in COPD patients supports the presence of an impaired antioxidant defense system in this group.


KEY WORDS: Pulmonary disease, chronic obstructive; Oxidative stress; Systematic review

inizio pagina